

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

FURTHER POSTPONEMENT OF BOARD MEETING

The board of directors (the “**Board**”) of PuraPharm Corporation Limited (the “**Company**”) refers to the announcements issued by the Company dated 17 March 2025 and 27 March 2025, in relation to the notice of Board meeting and postponement of the Board meeting (the “**Board Meeting**”) to be held for the purpose of, among others, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2024 (the “**Annual Results**”) and its publication, and considering the payment of a final dividend, if any.

As additional time is required to finalise the 2024 Annual Results, the Board hereby announces that the Board Meeting will be further postponed to Monday, 31 March 2025.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 28 March 2025

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.